Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 2/20 | 0.59 |
| ▸ | ACHE | P22303 | 1/20 | 0.59 |
| ▸ | BACE1 | P56817 | 1/20 | 0.59 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.57 |
| ▸ | CCR5 | P51681 | 1/20 | 0.55 |
| ▸ | UBE2M | P61081 | 2/20 | 0.55 |
| ▸ | DCUN1D1 | Q96GG9 | 2/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | THRB | P10828 | 1/20 | 0.52 |
| ▸ | DRD4 | P21917 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4211121 | 1.00 | OPRM1 (0.61) | OPRM1CHRM2CHRM3SLC2A1ACHE | |
| Hydrochloric Acid SCHEMBL4207721 | 0.99 | OPRM1 (0.60) | OPRM1CHRM2CHRM3SLC2A1ACHE | |
| Oxalic Acid SCHEMBL4208908 | 0.98 | OPRM1 (0.59) | OPRM1CHRM2CHRM3SLC2A1ACHE | |
| SCHEMBL340490 | 0.95 | UBE2M (0.61) | OPRM1CHRM2CHRM3SLC2A1ACHE | |
| SCHEMBL340505 | 0.94 | ACHE (0.55) | OPRM1CHRM2CHRM3SLC2A1ACHE | |
| SCHEMBL3707074 | 0.94 | ACHE (0.55) | OPRM1CHRM2CHRM3SLC2A1ACHE | |
| SCHEMBL341808 | 0.89 | SLC2A1 (0.50) | OPRM1CHRM2CHRM3SLC2A1ACHE | |
| SCHEMBL5540777 | 0.89 | SLC2A1 (0.50) | OPRM1CHRM2CHRM3SLC2A1ACHE | |
| SCHEMBL5329449 | 0.89 | HTR2A (0.59) | OPRM1CHRM2CCR5UBE2MDCUN1D1 | |
| SCHEMBL340169 | 0.89 | HTR2A (0.59) | OPRM1CHRM2CCR5UBE2MDCUN1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030220316-A1 | Azacyclic compounds | ACADIA PHARMACEUTICALS INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1263729-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | Acadia Pharmaceuticals Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| WO-2001066521-A1 | AZACYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF SEROTONIN RELATED DISEASES | ACADIA PHARMACEUTICALS, INC. (US) | 2001-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030220316-A1 | Azacyclic compounds | HTR6, TPMT, HNMT | OPRM1 210/4885CHRM2 136/4885CHRM3 348/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.